Bexmarilimab (Clevegen) development update
· Accumulating MATINS data build foundation for further clinical development · Five patient cohorts in MATINS study Part II already fully recruited · Higher frequency of dosing introduced to investigate potential for enhanced clinical responses · Three new trials will study bexmarilimab treatment in neoadjuvant setting, in combination with PD(L)-1 checkpoint inhibitor and in haematological malignanciesCompany announcement, 23 November 2020 at 9.00 AM (EET) TURKU – FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), the clinical stage biopharmaceutical company,